Ana Sayfa Biyoteknoloji Türkiye’nin biyobenzerlerde hızlanması gerekiyor. Dördüncü biyobenzer Trastuzumab ABD’de kullanıma verildi.

Türkiye’nin biyobenzerlerde hızlanması gerekiyor. Dördüncü biyobenzer Trastuzumab ABD’de kullanıma verildi.

Teva -Celltrion ABD’de dördüncü  biyobenzer  Trastuzumab’ ( Herzuma ) kullanıma  verdi. Fiyatı referans  ürün Herceptin’in % 10 altında

akk@winally.com

Teva, Celltrion Launch Fourth Trastuzumab Biosimilar

Teva Pharmaceuticals USA and Celltrion Healthcare have launched the fourth trastuzumab biosimilar, Herzuma, at a 10% discount to the cost of reference product Herceptin.
Three months after its FDA approval, a fourth trastuzumab biosimilar has been launched. Teva Pharmaceuticals USA and Celltrion Healthcare announced the market availability of Herzuma (trastuzumab-pkrb), an injectable biosimilar with the same indications as the Herceptin reference product.

The biosimilar arrival on market follows launches of other biosimilars for trastuzumab by Pfizer (Trazimera), Mylan/Biocon (Ogivri), Amgen/Allergan (Kanjinti). An additional trastuzumab biosimilar approved but not yet launched is Samsung Bioepis’ Ontruzant.